WEBULL

Boston Scientific (BSX) Recalls Endoscopy Devices, Is The Stock A Bargain?

Simply Wall St · 1d ago

Boston Scientific (BSX) is under scrutiny after a series of voluntary Class II recalls of its CRE and CRE Pro Wireguided endoscopy devices, prompted by potential sterile packaging breaches affecting tens of thousands of units globally.

See our latest analysis for Boston Scientific.

The recalls arrive after a period of sharp share price weakness, with Boston Scientific’s stock down 30.53% on a 3 month share price return basis and 52.89% year to date. The 1 year total shareholder return has declined 57.36%, suggesting momentum has been fading despite earlier growth in the underlying business.

If this kind of event driven move has you reassessing your watchlist, it can be useful to look across other healthcare technology opportunities using the 39 healthcare AI stocks

After a 52.89% year to date share price decline, the question with Boston Scientific is simple but important: has most of the repricing already happened, or is the bulk of any potential upside still ahead from here?

Most Popular Narrative: 54.9% Undervalued

According to the most followed Boston Scientific narrative, the latest close at $44.62 sits well below an assessed fair value of $98.90, putting a spotlight on how the recent sell off compares to long term potential.

The immediate impact of the Penumbra acquisition has been somewhat heavy on the stock’s valuation for a few key reasons: * Earnings Dilution: The acquisition is expected to be dilutive to adjusted earnings per share (EPS) by approximately $0.06 to $0.08 in the first full year. Investors often react to this "EPS drag" by pulling back, which we have seen in the recent price dips.

Read the complete narrative.

Want to see why this narrative still assigns a much higher fair value to Boston Scientific? The core assumptions rest on future earnings power, richer margin potential and how those feed into long run cash flows. The full narrative spells out the revenue trajectory, profitability profile and discount rate that have to hold for $98.90 to make sense.

Result: Fair Value of $98.90 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Boston Scientific still faces key risks, including the successful integration of Penumbra and the management of higher debt levels, which could weigh on flexibility if conditions tighten.

Find out about the key risks to this Boston Scientific narrative.

Next Steps

With sentiment on Boston Scientific clearly mixed, this is a moment to move fast, review the numbers firsthand and decide where you stand by weighing the 4 key rewards.

Looking for more investment ideas beyond Boston Scientific?

If Boston Scientific has you rethinking where to focus next, it is worth scanning a few different angles so you do not miss other compelling setups.

Use the Simply Wall St Screener to quickly compare fresh ideas, narrow your watchlist, and pressure test whether Boston Scientific still deserves a spot alongside new candidates.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.